Adakveo Market Report 2026

Adakveo Market Overview

• The Adakveo market growth in the historic period has been driven by limited treatment options for sickle cell disease, high burden of vaso occlusive crises • Market expansion is supported by growth in sickle cell patient population, expansion of access programs • Growth Driver: Rising Prevalence Of Sickle Cell Disease Driving Growth Of The Adakveo Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Adakveo Market?

Adakveo refers to a prescription drug that prevents vaso-occlusive crises in patients with sickle cell disease. It works by targeting P-selectin to reduce blood cell clumping and inflammation. Adakveo is used to lower the number of painful vaso-occlusive crises in people with sickle cell disease. The main indications in the adakveo market are sickle cell disease (adults and pediatric patients) and vaso-occlusive crisis prevention. Sickle cell disease refers to a group of inherited blood disorders characterized by abnormal hemoglobin, known as hemoglobin S. The various routes of administration include intravenous injection, infusion therapy, and oral, and several distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies. The different end-users encompass hospitals, clinics, ambulatory care, and home care.

What Is The Adakveo Market Growth Forecast?

The growth in the forecast period can be attributed to growth in sickle cell patient population, expansion of access programs, increased focus on preventive therapies, rising orphan drug investments, improved clinical guidelines adoption. Major trends in the forecast period include rising use of targeted therapies in sickle cell disease, growing focus on vaso occlusive crisis prevention, increased adoption of p selectin inhibitors, expansion of disease modifying treatments, improved long term management of rare blood disorders.

Global Adakveo Market Segmentation

1) By Indication: Sickle Cell Disease (Adults and Pediatric Patients), Vaso-Occlusive Crisis Prevention 2) By Route Of Administration: Intravenous Injection, Infusion Therapy, Oral 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End-User: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Adakveo Market?

The increasing prevalence of sickle cell disease is expected to propel the growth of the adakveo market going forward. Sickle cell disease (SCD) refers to a group of inherited blood disorders caused by the presence of abnormal hemoglobin, known as hemoglobin S, in red blood cells. The increasing prevalence of sickle cell disease can be attributed to factors such as higher birth rates in regions with endemic malaria, genetic inheritance patterns, and improved survival rates due to advances in medical care, which allow more individuals to live longer with the condition. Adakveo helps sickle cell disease patients by reducing the frequency of vaso-occlusive crises, which are painful episodes caused by the blockage of blood flow in small vessels, through its mechanism of action that selectively inhibits the adhesion of sickle cells to blood vessel walls, thereby improving blood flow and alleviating the symptoms of this debilitating condition. For instance, in July 2024, according to the Pennsylvania Bar Institute (PBI), a US-based organization, in 2021, approximately 7.74 million people had sickle cell disease (SCD). The number of newborns diagnosed annually is projected to increase from 275,000 in 2021 to over 400,000 by 2050. Therefore, the increasing prevalence of sickle cell disease is driving the adakveo industry. A rise in healthcare expenditure is expected to boost the growth of the adakveo market going forward. Healthcare expenditure is attributed to the financial investment made by governments, private insurers, and individuals in the healthcare system to improve and expand medical services. Healthcare expenditure supports Adakveo by enabling greater investment in innovative treatments for sickle cell disease, improving patient access to this targeted therapy, which helps reduce the burden of vaso-occlusive crises and enhances the quality of life for patients, especially in regions with advanced healthcare systems and adequate funding for specialty drugs. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending in the UK grew by 5.6% from 2022 to 2023, a significant increase compared to the 0.9% growth in 2022. In 2023, the UK's healthcare expenditure totaled approximately $317.63 billion (£292 billion). Thus, the rise in healthcare expenditure will drive the growth of the adakveo industry. The increasing focus on targeted therapies is expected to propel the growth of the adakveo market going forward. Targeted therapies are treatments that specifically target and inhibit molecular abnormalities in cancer or other diseases to improve treatment precision and minimize harm to healthy cells. The rising focus on targeted therapies is primarily driven by the advancements in precision medicine, which enables personalized, more effective treatments based on individual genetic profiles. Adakveo enhances targeted therapies by specifically binding to P-selectin, reducing vaso-occlusive crises in sickle cell patients. It improves treatment precision by addressing a key driver of inflammation and adhesion, leading to fewer pain episodes and better clinical outcomes. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved 6 gene therapy products in 2023, up from 5 approvals in 2022. Therefore, the increasing focus on targeted therapies is driving the growth of the adakveo industry.

Key Players In The Global Adakveo Market

Major companies operating in the adakveo market are Novartis AG

Regional Insights

North America was the largest region in the adakveo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Adakveo Market?

The adakveo market consists of sales of infusion sets, vials, injectable crizanlizumab, needles, and syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adakveo Market Report 2026?

The adakveo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adakveo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.